Regeneron is also developing REGN5458 and REGN5459, both anti-BCMA/CD3 tested for multiple myeloma (NCT03761108, NCT04083534), and several other CLC antibodies for various solid tumors (please see Supplementary Table S1). Here, TNFRSF17 is linked to AL amyloidosis.